$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Gilteritinib maintenance therapy shows benefit in MRD+FLT 3-mutant AML after HCT
2026-02-01 22:25:32
Check Details
Effect of Lorlatinib on brain metastasis
2026-02-01 22:25:32
Check Details
What should I do if I become resistant to Lorlatinib?
2026-02-01 22:25:32
Check Details
Bangladesh Everest version of Lorlatinib
2026-02-01 22:25:32
Check Details
How much does a box of genuine lorlatinib cost? The minimum price for generic drugs is about one to two thousand
2026-02-01 22:25:32
Check Details
What is the Medicare pricing of Lorlatinib?
2026-02-01 22:25:32
Check Details
Lorlatinib survival
2026-02-01 22:25:32
Check Details
Can lorlatinib treat small cell lung cancer?
2026-02-01 22:25:32
Check Details
Best time to take Lorlatinib
2026-02-01 22:25:32
Check Details
Keep up with current events! Revealing the latest treatment trends of lorlatinib
2026-02-01 22:25:32
Check Details
Get it now! Latest usage guidelines for lorlatinib in 2024
2026-02-01 22:25:32
Check Details
Newly launched in 2024! Lorlatinib latest price list
2026-02-01 22:25:32
Check Details
1
2
...
440
441
442
443
444
445
446
...
10236
10237
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Filgotinib JAK1 Inhibitor: RA and Ulcerative Colitis Dosing, Infection/Thrombosis Risks, Pregnancy Contraindication
2
Daprodustat for Dialysis CKD Anemia: HIF Mechanism, Thrombotic Black Box Warning, Blood Pressure and GI Monitoring
3
Pemigatinib for FGFR2-Rearranged Cholangiocarcinoma: Eligibility, Response Limits, Hyperphosphatemia and Ocular Monitoring
4
Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs
5
Bosentan Key Prescribing Points: Indication, Dosage, Risks, and Monitoring
6
Ambrisentan and IgA Nephropathy: Does It Reduce Proteinuria and Is It Safe?
7
Stiripentol for Dravet Syndrome With Clobazam: Weight-Based Dosing, Food Administration, Somnolence and Blood Count Monitoring
8
In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances
9
Acalabrutinib BTK Covalent Inhibition: CLL/SLL Signaling Blockade, Non-Selective Effects, and Progression Monitoring
10
Bosutinib for Ph+ CML: Eligible Populations, Food-Dependent Dosing, Diarrhea and Hepatotoxicity Monitoring
11
Hovilpri (Pritelivir) Oral Anti-HSV: Immunocompromised Adults With Acyclovir-Refractory Mucocutaneous Lesions, 63% Healing at 28 Days
12
Venetoclax BCL-2 Inhibitor: CLL/SLL and AML Ramp-Up, Tumor Lysis Prevention, and Selected Overseas Combination Updates